Should Value Investors Pick Turkcell Iletisim (TKC) Stock?

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put, Turkcell Iletisim Hizmetleri A.S. TKC stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, Turkcell Iletisim has a trailing twelve months PE ratio of 15.35, as you can see in the chart below:

This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 compares in at about 18.4. If we focus on the stock’s long-term PE trend, the current level puts Turkcell Iletisim’s current PE ratio somewhat above its midpoint (which is 10.80) over the past five years.

Also, the stock’s PE compares favorably with the Zacks Wireless Non-US industry’s trailing twelve months PE ratio, which stands at 18.62. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.

We should also point out that Turkcell Iletisim has a forward PE ratio (price relative to this year’s earnings) of just 8.69, so it is fair to say that a slightly more value-oriented path can be expected for Turkcell Iletisim’s stock in the near future.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, Turkcell Iletisim has a P/S ratio of 1.23. This is noticeably lower than the S&P 500 average, which comes in at 3.24 right now. Also, as we can see in the chart below, this is somewhat below the highs for this stock in particular over the past few years.

If anything, this suggests some level of undervalued trading—at least compared to historical norms.

Broad Value Outlook

In aggregate, Turkcell Iletisim currently has a Value Style Score of A, putting it into the top 20% of all stocks we cover from this look. This makes TKC a solid choice for value investors, and some of its other key metrics make this pretty clear too.

For example, the PEG ratio for Turkcell Iletisim is just 0.61, a level that is considerably lower than the industry average of 1.26. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Additionally, its P/CF ratio (another great indicator of value) comes in at 4.00, which is slightly better than the industry average of 4.14. Clearly, TKC is a solid choice on the value front from multiple angles.

What About the Stock Overall?

Though Turkcell Iletisim might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of A and a Momentum score of C. This gives TKC a VGM score—or its overarching fundamental grade—of A. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been disappointing. The current year has seen one estimate go lower in the past sixty days compared to none higher, while the full-year 2020 estimate has seen one downward and no upward revision in the same time period.

This has had a noticeable impact on the consensus estimate, as the current year consensus estimate has fallen 1.44% in the past two months, while the full-year 2020 estimate has declined 1.1%. in the same time period. You can see the consensus estimate trend and recent price action for the stock in the chart below:

This bearish trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.

Bottom Line

Turkcell Iletisim is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (bottom 11% out of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about this company overall.In fact, over the past one year, the sector has clearly underperformed the broader market, as you can see below:

So, value investors might want to wait for estimates, analyst sentiment and broader factors to turn favorable in this name first, but once that happens, this stock could be a compelling pick.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research